BofA upgraded Acadia Pharmaceuticals (ACAD) to Buy from Neutral with a $29 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee
- Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
- Acadia Pharmaceuticals price target lowered to $29 from $31 at BofA
- Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA
- ACADIA Pharmaceuticals Charts Growth Path After Record Year